Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Treg-mediated immunosuppression involves activation of the Notch-HES1 axis by membrane-bound TGF-β
Marina Ostroukhova, … , rabir Ray,, Anuradha Ray
Marina Ostroukhova, … , rabir Ray,, Anuradha Ray
Published April 3, 2006
Citation Information: J Clin Invest. 2006;116(4):996-1004. https://doi.org/10.1172/JCI26490.
View: Text | PDF
Research Article Immunology

Treg-mediated immunosuppression involves activation of the Notch-HES1 axis by membrane-bound TGF-β

  • Text
  • PDF
Abstract

Studies in humans and mice show an important role for Tregs in the control of immunological disorders. The mechanisms underlying the immunosuppressive functions of Tregs are not well understood. Here, we show that CD4+ T cells expressing Foxp3 and membrane-bound TGF-β (TGF-βm+Foxp3+), previously shown to be immunosuppressive in both allergic and autoimmune diseases, activate the Notch1–hairy and enhancer of split 1 (Notch1-HES1) axis in target cells. Soluble TGF-β and cells secreting similar levels of soluble TGF-β were unable to trigger Notch1 activation. Inhibition of Notch1 activation in vivo reversed the immunosuppressive functions of TGF-βm+Foxp3+ cells, resulting in severe allergic airway inflammation. Integration of the TGF-β and Notch1 pathways may be an important mechanism for the maintenance of immune homeostasis in the periphery.

Authors

Marina Ostroukhova, Zengbiao Qi, Timothy B. Oriss, Barbara Dixon-McCarthy, rabir Ray,, Anuradha Ray

×

Figure 5

Reversal of suppression by TGF-βm+ cells by inhibition of Notch1 signaling.

Options: View larger image (or click on image) Download as PowerPoint
Reversal of suppression by TGF-βm+ cells by inhibition of Notch1 signali...
(A) The γ-secretase inhibitor L-685,458 inhibits Notch1-induced HES1 activation in stimulated CD4+ T cells. Naive CD4+ T cells were stimulated with soluble anti-CD3 (2 μg/ml) plus APCs for 16 hours in the presence or absence of L-685,458 or 0.1% DMSO (vehicle). Nuclear extracts were prepared, and presence of HES1 was determined by immunoblotting. CREB-1 expression was assessed as a control for protein loading. (B) The γ-secretase inhibitor reverses the suppressive functions of TGF-βm+ cells. Mice were first exposed to PBS (inflammation group; Inf.) or 1% OVA (tolerance group; Tol.) daily for 10 days and were then immunized with OVA/alum on days 21 and 27. Splenic CD4+ T cells isolated on day 34 were stimulated in vitro with different concentrations of OVA (1–200 μg/ml) and mitomycin C–treated, T cell–depleted APCs at equivalent cell numbers (105 cells each per well). In mixed cultures containing CD4+ T cells from both groups, twice the number of cells from the tolerance group was added. The γ-secretase inhibitor L-685,458 was added at a concentration of 1 or 10 μM. After 72 hours of incubation, cells were pulsed with [3H]thymidine to assess cell proliferation. The proliferative response of CD4+ T cells from naive mice is shown as a negative control. *P < 0.05, mixed cultures with inhibitor treatment versus cultures without treatment. Each data point represents the mean ± SEM of triplicate wells. Shown is a representative experiment of 3.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts